FGFR2 and lung carcinoma: For example, KL expression has been shown to exert a protective effect against overall mortality in non-diabetic, pre-dialysis chronic kidney disease (Yang et al., 2020), whereas FGFR2 expression was associated with increased risk of poor prognosis in patients with IPF and lung cancer (Li et al., 2018).